Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.

Trial Details

NCT ID

NCT06586242

Phase

PHASE2

Sponsor

Xijing Hospital

Status

RECRUITING

Cancer Type

Esophageal Cancer

Interventions

Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin

Locations (sample)

Xi'an, Shaan'xi, China|34.25833,108.92861

Key Eligibility Criteria

1\. only those who meet all the following requirements can be enrolled in this trial: 1. age 18-75 years old, both male and female;
2\. according to gastroscope / ultrasonic gastroscope biopsy, the pathology suggests esophageal cancer, and the clinical diagnosis is ct2n1-3m0 or …
3\. patients with non cervical esophageal cancer;
4\. have not received previous systemic and local treatment for esophageal cancer according to RECIST 1 1 criteria at least one measurable lesion w…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →